TY - JOUR
T1 - Activation of Notch signaling in a xenograft model of brain metastasis
AU - Nam, Do Hyun
AU - Jeon, Hye Min
AU - Kim, Shiyeon
AU - Kim, Mi Hyun
AU - Lee, Young Ju
AU - Lee, Min Su
AU - Kim, Hyunggee
AU - Joo, Kyeung Min
AU - Lee, Dong Sup
AU - Price, Janet E.
AU - Bang, Sa Ik
AU - Park, Woong Yang
PY - 2008/7/1
Y1 - 2008/7/1
N2 - Purpose: The potential of metastasis can be predicted from clinical features like tumor size, histologic grade, and gene expression patterns. We examined the whole-genome transcriptomic profile of a xenograft model of breast cancer to understand the characteristics of brain metastasis. Experimental Design: Variants of the MDA-MB-435 cell were established from experimental brain metastases. The LvBr2 variant was isolated from lesions in a mouse injected in the left ventricle of the heart, and these cells were used for two cycles of injection into the internal carotid artery and selection of brain lesions, resulting in the Br4 variant. To characterize the different metastatic variants, we examined the gene expression profile of MDA-MB-435, LvBr2, and Br4 cells using microarrays. Results: We could identify 2,016 differentially expressed genes in Br4 by using the F test. Various metastasis-related genes and a number of genes related to angiogenesis, migration, tumorigenesis, and cell cycle were differentially expressed by the Br4 cells. Notably, the Notch signaling pathway was activated in Br4, with increased Jag2 mRNA, activated Notch intracellular domain, and Notch intracellular domain/CLS promoter-luciferase activity. Br4 cells were more migratory and invasive than MDA-MB-435 cells in collagen and Matrigel Transwell assays, and the migration and invasion of Br4 cells were significantly inhibited by inactivation of Notch signaling using DAPT, a 7-secretase inhibitor, and RNA interference - mediated knockdown of Jagged 2 and Notchl. Conclusions: Taken together, these results suggest that we have isolated variants of a human cancer cell line with enhanced brain metastatic properties, and the activation of Notch signaling might play a crucial role in brain metastasis.
AB - Purpose: The potential of metastasis can be predicted from clinical features like tumor size, histologic grade, and gene expression patterns. We examined the whole-genome transcriptomic profile of a xenograft model of breast cancer to understand the characteristics of brain metastasis. Experimental Design: Variants of the MDA-MB-435 cell were established from experimental brain metastases. The LvBr2 variant was isolated from lesions in a mouse injected in the left ventricle of the heart, and these cells were used for two cycles of injection into the internal carotid artery and selection of brain lesions, resulting in the Br4 variant. To characterize the different metastatic variants, we examined the gene expression profile of MDA-MB-435, LvBr2, and Br4 cells using microarrays. Results: We could identify 2,016 differentially expressed genes in Br4 by using the F test. Various metastasis-related genes and a number of genes related to angiogenesis, migration, tumorigenesis, and cell cycle were differentially expressed by the Br4 cells. Notably, the Notch signaling pathway was activated in Br4, with increased Jag2 mRNA, activated Notch intracellular domain, and Notch intracellular domain/CLS promoter-luciferase activity. Br4 cells were more migratory and invasive than MDA-MB-435 cells in collagen and Matrigel Transwell assays, and the migration and invasion of Br4 cells were significantly inhibited by inactivation of Notch signaling using DAPT, a 7-secretase inhibitor, and RNA interference - mediated knockdown of Jagged 2 and Notchl. Conclusions: Taken together, these results suggest that we have isolated variants of a human cancer cell line with enhanced brain metastatic properties, and the activation of Notch signaling might play a crucial role in brain metastasis.
UR - http://www.scopus.com/inward/record.url?scp=48249107113&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-4039
DO - 10.1158/1078-0432.CCR-07-4039
M3 - Article
C2 - 18593982
AN - SCOPUS:48249107113
SN - 1078-0432
VL - 14
SP - 4059
EP - 4066
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 13
ER -